Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Go back to Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 82.08 +0.26 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $81.82 | 52 Week High | $8.22 | |||
| Open | $83.00 | 52 Week Low | $3.07 | |||
| Day High | $84.00 | P/E | N/A | |||
| Day Low | $81.95 | EPS | $-1.30 | |||
| Volume | 213,739 | |||||
| (NASDAQ: MDGL) | Delayed: 505.29 -0.46 (0.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $505.75 | 52 Week High | $18.24 | |||
| Open | $513.23 | 52 Week Low | $6.60 | |||
| Day High | $515.00 | P/E | N/A | |||
| Day Low | $500.80 | EPS | $0.00 | |||
| Volume | 62,149 | |||||
